Brewin Dolphin LTD Autolus Therapeutics PLC Transaction History

Brewin Dolphin LTD

  • $2.08 Billion
  • Q2 2022

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 09, 2023
SELL
$5.32 - $7.37 $4,963 - $6,876
-933 Reduced 1.98%
46,217 $303 Million
Q1 2021

Nov 09, 2023
BUY
$5.49 - $9.36 $251,167 - $428,220
45,750 Added 3267.86%
47,150 $270 Million
Q4 2020

Nov 09, 2023
BUY
$8.13 - $12.79 $11,382 - $17,906
1,400 New
1,400 $12.5 Million

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Brewin Dolphin LTD Portfolio

Follow Brewin Dolphin LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brewin Dolphin LTD, based on Form 13F filings with the SEC.

News

Stay updated on Brewin Dolphin LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email